Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560051 | 1.00 | HTR1A (0.42) | HTR1AADRA1DADRA1AADRA1BSYK | |
| SCHEMBL30560049 | 0.87 | SYK (0.39) | SYKAURKAAURKB | |
| SCHEMBL24507531 | 0.87 | SYK (0.39) | SYKAURKAAURKB | |
| SCHEMBL30119880 | 0.83 | AURKA (0.46) | CDK2AURKAAURKB | |
| SCHEMBL24507576 | 0.83 | AURKA (0.46) | CDK2AURKAAURKB | |
| SCHEMBL26202970 | 0.82 | EGFR (0.47) | TGFBR1TP53MAPK10AURKAAURKB | |
| SCHEMBL24507283 | 0.81 | SLC22A12 (0.38) | SYKTGFBR1 | |
| SCHEMBL29716074 | 0.81 | SLC22A12 (0.38) | SYKTGFBR1 | |
| SCHEMBL24507276 | 0.81 | MAPK14 (0.36) | SYKTGFBR1MAPK14CCNE1CDK2 | |
| SCHEMBL30560048 | 0.81 | MAPK14 (0.36) | SYKTGFBR1MAPK14CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259145-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022126133-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY,INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022126133-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY,INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | ACVR1, ALK, ACVRL1 | HTR1A 3125/4885ADRA1D 1072/4885ADRA1A 1379/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | HTR1A 3125/4885ADRA1D 1072/4885ADRA1A 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.